Glaxo Blood Cancer Treatment Wins Backing From FDA Committee

(Bloomberg) -- GlaxoSmithKline Plc took a step forward in its bid for U.S. approval of a novel blood cancer drug, after a panel advising the Food and Drug Administration voted in favor of its use.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.